Coiled Therapeutics plc (COIL): AO-252 Phase I trial progress
This situation live
COIL Coiled Therapeutics plc
8 Apr 2026 · Dose escalation; moving to expansion cohorts · −19% until the next step
The Company is targeting enrolment of 40 patients by Q3 2026.
6 May 2026 · Dose escalation finishing; expansion cohorts accelerating · +0% until the next step
The Board's immediate priorities include the completion of open label Phase I dose escalation in H1 2026, the introduction of a next-generation formulation of AO-252 to optimise drug exposure, and the
28 Sep 2026 · Reformulation under way; efficacy data pushed to 2027 · −5% since
During 2027, we expect to develop a more comprehensive clinical package including preliminary efficacy data, a safety database of approximately 50 patients and biomarker validation.
AO-252 Phase I trial progress
Reformulation under way; efficacy data pushed to 2027
DEC31
Next: Initial safety and PK data from new softgel formulation cohorts in 68 days
Every step · 3
- 8 Apr 2026 Dose escalation; moving to expansion cohorts – The Company is targeting enrolment of 40 patients by Q3 2026. ↗
- 6 May 2026 Dose escalation finishing; expansion cohorts accelerating – The Board's immediate priorities include the completion of open label Phase I dose escalation in H1 2026, the introduction of a next-generation formulation... ↗
- 28 Sep 2026 Reformulation under way; efficacy data pushed to 2027 – During 2027, we expect to develop a more comprehensive clinical package including preliminary efficacy data, a safety database of approximately 50 patients... ↗
What is happening
Coiled Therapeutics plc: AO-252 Phase I trial progress – Reformulation under way; efficacy data pushed to 2027. ['Reformulation under way; efficacy data pushed to 2027']
- In short
- After the March 2026 reverse takeover and £8.5m placing, Coiled reported 80% CBR on twice-daily dosing on 8 April 2026. The 30 September 2026 interim results add a new lipid softgel formulation (first patient dosed August 2026, six patients enrolled September). Expansion-cohort efficacy data now fall in 2027, not H2 2026.
- Announced
- 8 Apr 2026 · Dose escalation; moving to expansion cohorts
- Latest
- 28 Sep 2026 · Reformulation under way; efficacy data pushed to 2027
- H2 2026
- Expansion cohort efficacy and safety readouts in ovarian and prostate cancer
- Enrolment target
- 40 patients in expansion cohorts by Q3 2026
- Data readouts
- Ovarian and prostate expansion efficacy and safety data in H2 2026, material readouts by Q4 2026
- Funding
- £8.5m placing at 10p, said to fund key inflection points in 2026 and 2027
- After the data
- Registrational planning and discussions with potential strategic partners
- Dosing target
- Up to 30 patients on new formulation by end of 2026
- Efficacy data
- Preliminary efficacy and ~50-patient safety database in 2027, previously H2 2026 readouts
- Cash
- £5,099,604 at 30 June 2026; H1 net loss £3,851,679
What comes next
Initial safety and PK data from new softgel formulation cohorts (31 Dec 2026).
Briefing Pro
New to Coiled Therapeutics plc? Get up to speed in 2 minutes.
What it does, how it got here, what management promised and delivered – written from its own announcements.
Get the COIL briefing →From the company's own announcements. Not investment advice.
Also at Coiled Therapeutics plc 1 open
Insider conviction1 director buying – £39k in 1 buy
Large acquisition / reverse takeoverAO-252 licence to Roquefort – AIM Readmission completed · closed
Coiled Therapeutics plc – company page →